|
End-of-day quote
Shanghai S.E.
28/10/2026
|
5-day change | 1st Jan Change | ||
| 13.68 CNY | -0.15% |
|
-3.05% | -9.22% |
| 10-26 | Citi Adjusts Tasly Pharmaceutical Group's Price Target to 16.50 Yuan | MT |
| 10-15 | Huachuang Securities Starts Tasly Pharmaceutical Group at Add with 17.20 Yuan Price Target | MT |
Company Valuation: Tasly Pharmaceutical Group Co., Ltd
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 23,778 | 15,988 | 25,427 | 21,603 | 22,514 | 20,437 | - | - |
| Change | - | -32.76% | 59.04% | -15.04% | 4.22% | -9.22% | - | - |
| Enterprise Value (EV) 1 | 23,086 | 14,968 | 23,635 | 20,197 | 22,465 | 18,893 | 14,725 | 18,068 |
| Change | - | -35.16% | 57.9% | -14.55% | 11.23% | -15.9% | -22.06% | 22.7% |
| P/E | 10.1x | -63.3x | 23.6x | 22.6x | 20.4x | 15.4x | 13.1x | 11.4x |
| PBR | 1.83x | 1.3x | 2.06x | 1.81x | 1.82x | 1.54x | 1.42x | 1.3x |
| PEG | - | 1x | -0x | -2x | 1.3x | 0.8x | 0.8x | 0.7x |
| Capitalization / Revenue | 2.99x | 1.86x | 2.93x | 2.54x | 2.73x | 2.52x | 2.2x | 2.04x |
| EV / Revenue | 2.9x | 1.74x | 2.72x | 2.38x | 2.73x | 2.33x | 1.59x | 1.8x |
| EV / EBITDA | 7.32x | 50.8x | 14.2x | 12.8x | 12.3x | 8.04x | 6.34x | 6.88x |
| EV / EBIT | 8.45x | -97.9x | 19.2x | 18.8x | 16.6x | 10.5x | 8.29x | 8.97x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | 0.33 | 0.33 | 0.33 | 0.2 | 0.1 | 0.3852 | 0.458 | 0.558 |
| Rate of return | 2.08% | 3.07% | 1.94% | 1.38% | 0.66% | 2.82% | 3.35% | 4.08% |
| EPS 2 | 1.57 | -0.17 | 0.72 | 0.64 | 0.74 | 0.8897 | 1.043 | 1.202 |
| Distribution rate | 21% | -194% | 45.8% | 31.3% | 13.5% | 43.3% | 43.9% | 46.4% |
| Net sales 1 | 7,952 | 8,593 | 8,674 | 8,498 | 8,236 | 8,111 | 9,272 | 10,024 |
| EBITDA 1 | 3,153 | 294.6 | 1,663 | 1,578 | 1,820 | 2,350 | 2,324 | 2,626 |
| EBIT 1 | 2,733 | -153 | 1,228 | 1,076 | 1,350 | 1,798 | 1,775 | 2,014 |
| Net income 1 | 2,359 | -256.5 | 1,071 | 955.6 | 1,105 | 1,331 | 1,558 | 1,798 |
| Net Debt 1 | -691.9 | -1,020 | -1,792 | -1,406 | -48.5 | -1,544 | -5,712 | -2,369 |
| Reference price 2 | 15.85 | 10.76 | 17.02 | 14.46 | 15.07 | 13.68 | 13.68 | 13.68 |
| Nbr of stocks (in thousands) | 1,500,163 | 1,485,873 | 1,493,950 | 1,493,950 | 1,493,950 | 1,493,950 | - | - |
| Announcement Date | 30/03/22 | 27/03/23 | 15/04/24 | 24/02/25 | 06/02/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 15.4x | 2.33x | 8.05x | 2.81% | 3.07B | |
| 37.66x | 13.18x | 27.98x | 0.53% | 1,143B | |
| 39.33x | 6.61x | 18.6x | 1.99% | 647B | |
| 37.45x | 8.4x | 17.37x | 2.4% | 506B | |
| 21.46x | 5.22x | 12.98x | 2.51% | 384B | |
| 103.38x | 5.8x | 24.86x | 2.4% | 350B | |
| 21.99x | 5.69x | 13.69x | 2.94% | 293B | |
| 22.31x | 4.51x | 12.87x | 1.96% | 265B | |
| 28.42x | 7.28x | 13.03x | 2.25% | 242B | |
| -45.78x | 7.1x | 27.53x | 2.07% | 197B | |
| Average | 28.16x | 6.61x | 17.70x | 2.19% | 403.06B | |
| Weighted average by Cap. | 35.26x | 8.35x | 20.47x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 600535 Stock
- Valuation Tasly Pharmaceutical Group Co., Ltd
Select your edition
All financial news and data tailored to specific country editions
